Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Hawthorne, New York 10532


Purpose:

To compare the efficacy and safety of the test formulation Naftifine Hydrochloride Gel 2% to Naftin® (Naftifine Hydrochloride) Gel 2%


Study summary:

The purpose of this study is to compare the efficacy and safety of the test formulation Naftifine Hydrochloride Gel 2% to Naftin® (Naftifine Hydrochloride) Gel 2% in a six week study (four weeks after the end of two week treatment) in patients with tinea pedis.


Criteria:

Inclusion Criteria: - Male or non-pregnant, non-lactating females 18 years of age or older. - The sum of the clinical signs and symptoms scores of the target lesion is at least 4, including a minimum score of at least 2 for erythema and a minimum score of 2 for either scaling or pruritus. - Clinical diagnosis of interdigital tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot. - The presence of interdigital tinea pedis infection, confirmed by the observation of segmented fungal hyphae during a microscopic potassium hydroxide wet mount preparation. Exclusion Criteria: - Females who are pregnant, lactating or planning to become pregnant during the study period. - Use of antipruritics, including antihistamines within 72 hours prior to baseline visit. - Use of topical corticosteroids, antibiotics or antifungal therapies within 2 weeks prior to baseline visit. - Use of systemic corticosteroids, antibiotics or antifungal therapies within 1 month prior to baseline visit. - Use of oral Terbinafine or Itraconazole within 2 months prior to baseline visit. - Use of immunosuppressive medication or radiation therapy within 3 months prior to baseline visit. - Any known hypersensitivity to Naftifine Hydrochloride, or any component of the formulation. - Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface. - History of significant or current evidence of chronic infectious disease, system disorder, organ disorder, or other medical condition that would place patient at undue risk by participation or could jeopardize the integrity of the study evaluations. - Evidence of any concurrent dermatophytic infection of the toe nails or dermatological condition of the foot that may interfere with the investigator's evaluation of tinea pedis. - Patients with a past history of dermatophyte infections with a lack of response to antifungal therapy.


NCT ID:

NCT02335255


Primary Contact:

Study Director
Natalie Yantovskiy
Taro


Backup Contact:

N/A


Location Contact:

Hawthorne, New York 10532
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.